FDA
-
-
-
-
-
-
-
Organon closes license deal for copper IUD Miudella with Sebela
-
-
-
-
-
-
-
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe
-
-
-
-
-
-
-
Organon licenses hormone-free IUD MIUDELLA for up to $532.5 million
-
-
-
-
-
-
-
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
-
-
-
-
-
-
-
Organon Reports Results for the Second Quarter Ended June 30, 2025
-
-
-
-
-
-
-
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.
-
-
-
-
-
-
-
Organon (OGN) Issues Update on FDA Review of VTAMA Cream
-
328,833 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

